Halozyme appoints Michael LaBarre as chief scientific officer

US oncology biotech company Halozyme (Nasdaq: HALO) has appointed Michael LaBarre as chief scientific officer.

This will give Dr LaBarre responsibility for research and development of early pipeline assets, in addition to the role he already had in managing product development and Enhanze platform partnerships.

Helen Torley, president and chief executive, said: "Mike has deep experience characterizing early stage assets, making him an ideal leader for our research organization as we invest further in our promising pipeline. We have a full agenda for the second half of 2015 as we broaden the study of our investigational new drug PEGPH20 in multiple tumor types and prepare for our pivotal Phase III study in pancreatic cancer patients. I am pleased to have a proven leader of Mike's caliber to guide our research efforts as we invest for future growth."